These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24065278)

  • 21. Synthesis and in vitro anticancer and anti-HIV evaluation of new 2-mercaptobenzenesulfonamides.
    Pomarnacka E; Kornicka A
    Farmaco; 2001 Aug; 56(8):571-7. PubMed ID: 11601642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.
    Jia Q; Jiang X; Yu F; Qiu J; Kang X; Cai L; Li L; Shi W; Liu S; Jiang S; Liu K
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2393-5. PubMed ID: 22406118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
    Glenn MP; Pattenden LK; Reid RC; Tyssen DP; Tyndall JD; Birch CJ; Fairlie DP
    J Med Chem; 2002 Jan; 45(2):371-81. PubMed ID: 11784141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The design and discovery of novel amide CCR5 antagonists.
    Pryde DC; Corless M; Fenwick DR; Mason HJ; Stammen BC; Stephenson PT; Ellis D; Bachelor D; Gordon D; Barber CG; Wood A; Middleton DS; Blakemore DC; Parsons GC; Eastwood R; Platts MY; Statham K; Paradowski KA; Burt C; Klute W
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1084-8. PubMed ID: 19167884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
    Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
    Hale JJ; Budhu RJ; Holson EB; Finke PE; Oates B; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano S; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini E
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2741-5. PubMed ID: 11591514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
    Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
    J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region.
    Wang C; Wang X; Wang H; Pu J; Li Q; Li J; Liu Y; Lu L; Jiang S
    J Med Chem; 2021 Aug; 64(15):11460-11471. PubMed ID: 34261320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of HIV antiretroviral drug resistance.
    Chen TK; Aldrovandi GM
    Pediatr Infect Dis J; 2008 Aug; 27(8):749-52. PubMed ID: 18664987
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.
    Li G; Haney KM; Kellogg GE; Zhang Y
    J Chem Inf Model; 2009 Jan; 49(1):120-32. PubMed ID: 19166361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase.
    Sun Y; Xu W; Fan N; Sun X; Ning X; Ma L; Liu J; Wang X
    Bioorg Med Chem; 2017 Feb; 25(3):1076-1084. PubMed ID: 28082070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.
    Roche M; Borm K; Flynn JK; Lewin SR; Churchill MJ; Gorry PR
    Curr Top Med Chem; 2016; 16(10):1091-106. PubMed ID: 26324043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gold(I) complex of 1,1'-bis(diphenylphosphino) ferrocene-quinoline conjugate: a virostatic agent against HIV-1.
    Gama N; Kumar K; Ekengard E; Haukka M; Darkwa J; Nordlander E; Meyer D
    Biometals; 2016 Jun; 29(3):389-97. PubMed ID: 26922346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
    Nishizawa R; Nishiyama T; Hisaichi K; Hirai K; Habashita H; Takaoka Y; Tada H; Sagawa K; Shibayama S; Maeda K; Mitsuya H; Nakai H; Fukushima D; Toda M
    Bioorg Med Chem; 2010 Jul; 18(14):5208-23. PubMed ID: 20542438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
    Hoque MA; Arai T; Nishino N; Kim HJ; Ito A; Yoshida M
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6770-2. PubMed ID: 23021104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.
    Safarian D; Carnec X; Tsamis F; Kajumo F; Dragic T
    Virology; 2006 Sep; 352(2):477-84. PubMed ID: 16777164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
    Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
    Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs.
    Wu J; Liu X; Cheng X; Cao Y; Wang D; Li Z; Xu W; Pannecouque C; Witvrouw M; De Clercq E
    Molecules; 2007 Aug; 12(8):2003-16. PubMed ID: 17960101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.